Hudson Therapeutics and Shaperon Report Positive Result of Phase 2B Part 1 for Nugel at JPM 2025
DURHAM, NC, UNITED STATES, January 24, 2025 /EINPresswire.com/ -- Hudson Therapeutics and Shaperon announced on January 24th that they engaged in in-depth discussions about out-licensing their next-generation atopic dermatitis treatment, NuGel, with …